hypertension-induced hypertrophy are unknown, but there is suggestive evidence that contractile agonists may play an etiologic role. Khokhar and Slater 8 found that the urinary excretion of arginine vasopressin was elevated in some patients with essential hypertension as compared with normotensive control subjects. Also, Crofton et al 9 reported that, in the deoxycorticosterone-salt rat model of hypertension, arginine vasopressin appears to play a major role in both the development and maintenance of the hypertension. Further evidence that contractile agonists may play a role in some of the structural changes observed in hypertension is provided by the observation that converting enzyme inhibitors are more effective at preventing or reversing both smooth muscle cell 10 and myocardial cell 11 hypertrophy in the spontaneously hypertensive rat than direct vasodilators and that the effects of converting enzyme inhibitors on hypertrophy are greater than predicted based on the magnitude of decreases in blood pressure. The hypothesis that contractile agonists might play some direct role in regulation of smooth mus- cle cell growth is intriguing as it may explain how a smooth muscle cell might alter its mass in response to an induced change in its work load. Because growth factors and contractile agonists share many of the same intracellular signaling mechanisms, it is not surprising that contractile agonists, such as arginine vasopressin and angiotensin II, have been reported to induce proliferation of a number of cell lines.
T here is considerable interest in the mechanisms involved in smooth muscle cell growth control and the involvement of vasoactive peptides in this process. Vascular smooth muscle cells are capable of two different growth responses in vivo. Injury models of atherogenesis and coarctation models of hypertension are characterized by intimal migration and proliferation of smooth muscle cells. 1 -3 In contrast, in certain models of chronic hypertension, such as the spontaneously hypertensive rat and the two-kidney, one clip Goldblatt hypertension model, smooth muscle cell hypertrophy is the predominant growth response, 4 -7 and this hypertrophy is often accompanied by an increase in cell ploidy. 67 The mechanisms involved in hypertension-induced hypertrophy are unknown, but there is suggestive evidence that contractile agonists may play an etiologic role. Khokhar and Slater 8 found that the urinary excretion of arginine vasopressin was elevated in some patients with essential hypertension as compared with normotensive control subjects. Also, Crofton et al 9 reported that, in the deoxycorticosterone-salt rat model of hypertension, arginine vasopressin appears to play a major role in both the development and maintenance of the hypertension. Further evidence that contractile agonists may play a role in some of the structural changes observed in hypertension is provided by the observation that converting enzyme inhibitors are more effective at preventing or reversing both smooth muscle cell 10 and myocardial cell 11 hypertrophy in the spontaneously hypertensive rat than direct vasodilators and that the effects of converting enzyme inhibitors on hypertrophy are greater than predicted based on the magnitude of decreases in blood pressure. The hypothesis that contractile agonists might play some direct role in regulation of smooth mus-cle cell growth is intriguing as it may explain how a smooth muscle cell might alter its mass in response to an induced change in its work load. Because growth factors and contractile agonists share many of the same intracellular signaling mechanisms, it is not surprising that contractile agonists, such as arginine vasopressin and angiotensin II, have been reported to induce proliferation of a number of cell lines. 12 -15 However, studies by Campbell-Boswell and Robertson, 16 in which cultured human aortic smooth muscle cells were used, found that neither angiotensin II nor arginine vasopressin was mitogenic for smooth muscle cells in the absence of 10% fetal bovine serum (FBS). Interestingly, although angiotensin II enhanced the proliferation of the human smooth muscle cells in serum, arginine vasopressin inhibited smooth muscle cell proliferation in response to 10% FBS. Recently, we reported that angiotensin II induced hypertrophy of quiescent cultured rat aortic smooth muscle cells but did not stimulate cellular proliferation either alone or in combination with either 10% FBS or plateletderived growth factor (2.5 ng/ml). 17 In the present study, we have addressed whether contractile agonists other than angiotensin II can modulate smooth muscle cell growth by studying the effect of arginine vasopressin on both proliferation and hypertrophy of cultured rat aortic smooth muscle cells.
Materials and Methods

Cell Culture
Rat thoracic aortic smooth muscle cells were isolated and cultured as previously described. 17 Cells were harvested for passaging just before confluency (approximately 4-day intervals) with a trypsin-EDTA (0.05% trypsin, 0.02% EDTA, GIBCO Labs., Grand Island, New York) solution and plated at 3-5 xlO 3 cells/cm 2 . Passaged cells were grown in a one-to-one mixture of Dulbecco's Modified Eagle Medium (DMEM) (GIBCO Labs.) and Ham's F12 medium (F12, GIBCO Labs.), containing either 10% FBS (Hyclone Labs., Inc., Logan, Utah), Lglutamine (0.68 mM, Sigma Chemical Co., St. Louis, Missouri), penicillin (100 units/ml) and streptomycin (100 ixglvcA) (designated DF10) or insulin (5xl0~7M, Sigma Chemical Co.), transferrin (5 fig/ml, Sigma Chemical Co.), ascorbate (0.2 mM, Sigma Chemical Co.), L-glutamine and antibiotics (designated serumfree medium [SFM] ). This SFM has been described previously.
17
- 18 Cultures were used between passages 4 and 30. Cell cultures were incubated at 37° C in a humidified atmosphere of 5% CO 2 and 95% air with media changes every 2-3 days.
Growth Curves
Cultures were washed with a calcium-magnesiumfree phosphate-buffered saline (PBS) (mM): NaCl 137, Na 2 HPO 4 H]thymidine (2 jtCi/ml, 6.7 Ci/mmol, New England Nuclear, Boston, Massachusetts). At 24 hours, cultures were washed twice with PBS followed by one wash with 4° C 10% TCA and one wash with 22° C 10% TCA. Cells were then dissolved in 0.5iV NaOH and counted in 10 ml Readysafe (Beckman, Irvine, California) in a Beckman LS8100 liquid scintillation counter. Triplicate dishes were analyzed per sample.
Flow Microfluorimetric Analysis of Cellular DNA and Protein Content
Cultures were washed with PBS and harvested using trypsin-EDTA. Samples were centrifuged (113g, 6 minutes), fixed in 75% methanol/25% PBS on ice for 30 minutes, and then divided for separate protein and DNA staining. For the protein staining, samples were centrifuged (113g, 6 minutes), stained with FITC (75 ng/ml fluorescein isothiocyanate, Sigma Chemical Co.; 0.5 M NaHCO 3 , pH 8) on ice for 30 minutes, then centrifuged (113^, 6 minutes) and resuspended in 0.85% NaCl. For the measurement of DNA, cells were stained with Hoechst 33258 (Hoechst 33258, 0.58 /xg/ml, Sigma Chemical Co.; NaCl 145 mM; Tris 100 mM) after centrifugation (113g, 6 minutes). All samples for both protein and DNA measurements were kept on ice until analyzed on a Coulter Epics V fluorescenceactivated cell sorter (Hialeah, Florida). Cell clumping was less than 1% based on analysis of peak versus integrated fluorescence. Cold L-methionine (2.5 mg/ml) was added to the TCA to reduce nonspecific binding of free [ 
Statistics
All results were analyzed by either Student's t test or an analysis of variance combined with Newman-Keuls multiple range test for intergroup comparisons. Probabilities of 0.05 or less were considered statistically significant. Values reported in the text are mean±SEM. All experiments were performed at least twice.
Results
Arginine Vasopressin Does Not Stimulate Aortic Smooth Muscle Cell Proliferation
To determine whether arginine vasopressin was mitogenic for smooth muscle cells, cultures were plated in DF10 for 2 days then switched to SFM for 5 days to induce quiescence. Cells were then treated with arginine vasopressin (1 /xM), vehicle, or 10% FBS, and cell counts were performed at 0, 2, and 4 days ( Figure 1 ). Arginine vasopressin did not increase cell number above that of vehicle-treated control. Since growth of many cells requires factors present in serum, experiments were also performed in cells maintained in low serum containing media. Cells were plated in DF10 for 2 days then switched to 0.4% FBS for 5 days. Cultures were treated with arginine vasopressin (1 /xM) or vehicle, and incorporation data, flow microfluorimetric analysis of cellular DNA content showed that the majority of cells were in the GQ/G, peak with few cells in S+G 2 , and no differences were observed between arginine vasopressin-and vehicle-treated groups (Figure 3 ). There was no evidence of an increase in the fraction of cells with 4C DNA content in cells treated with arginine vasopressin as compared with controls.
Arginine Vasopressin Increases Smooth Muscle Cell Protein Content
Although arginine vasopressin did not induce cell proliferation, it did induce an increase in smooth muscle cell protein content. When quiescent smooth muscle cell cultures were treated with arginine vasopressin (1 /uM) or vehicle for 4 days and protein (Figure 4) show that protein is accumulated during a 4-day treatment period.
FIGURE 6. Bar graph depicting the effect of the specific vasopressin V t receptor antagonist [l-$-mercapto-fi,$-cyclopentamethylene propionic acid),2-(O-methyl)-tyrosinejarginine vasopressin (MCP) on arginine vasopressin (AVP)-induced increases in protein content. Quiescent postconfluent cultures were treated daily for 4 days with either A VP (1 fiM) or vehicle in the presence or absence of the antagonist (1 fiM). Values are mean±SEM. Only the AVP-treated group was significantly different from control (p<0.05, n=3, Student's t test). Similar results were obtained in two independent experiments.
Simultaneous Treatment of Quiescent Smooth Muscle Cells with Arginine Vasopressin and Angiotensin II
To address whether arginine vasopressin and angiotensin II were synergistic with respect to effects on smooth muscle cell growth, quiescent cells were treated simultaneously with concentrations of arginine vasopressin (1 /iM) and angiotensin II (1 fiM) that elicit maximal responses. Arginine vasopressin plus angiotensin II induced a greater increase in [ 35 S]methionine incorporation (0-24 hours) and a greater increase in protein content after 4 days of treatment than did treatment with either agonist alone ( Figure 7 ). Combined treatment of cells with arginine vasopressin plus angiotensin II did not stimulate proliferation as measured by cell counts (data not shown).
Discussion
We have previously reported that the potent vasoconstrictor angiotensin II induced a hypertrophic response in quiescent cultured aortic smooth muscle cells without detectable mitogenic activity. 17 This observation, together with observations impli- eating a role for angiotensin II in hypertrophic responses in vivo, 10 -11 as well as observations that polypeptide growth factors and contractile agonists have a number of properties in common has led to the hypothesis that contractile agonists" may be important regulators of smooth muscle cell growth. Here we report that another potent vasoconstrictor, arginine vasopressin, also induces an increase in protein synthesis and cellular hypertrophy, but not hyperplasia, of cultured rat aortic smooth muscle cells. Thus, induction of hypertrophy by contractile agonists is not unique to angiotensin II.
The mechanisms involved in contractile agonistinduced hypertrophy are at present unknown, but it is of interest that both arginine vasopressin and angiotensin II stimulate changes in a number of second messenger systems that are also altered in response to growth factors. 16 -19 -28 For example, arginine vasopressin and angiotensin II induce activation of inositol phosphates and diacyl glycerol signaling pathways, mechanisms also associated with proliferative stimulation of cells. In addition, a number of growth factors have been reported to cause contraction of aortic rings, showing high potency but low efficacy, 29 -30 whereas both arginine vasopressin and angiotensin II can induce proliferation in certain cell types. Arginine vasopressin is mitogenic for mouse 3T3 cells 12 and rat adrenal glomerulosa cells 13 and can potentiate hepatocyte regeneration after partial hepatectomy. 31 This suggests that the differences between growth factors and vasoactive peptides may be qualitative rather than quantitative. Since neither arginine vasopressin nor angiotensin II have been reported to stimulate tyrosine kinase activity in vascular smooth muscle cells, an intracellular response often seen with growth factors, 32 -35 it is interesting to speculate that the failure of angiotensin II and arginine vasopressin to elicit a mitogenic response may relate to their failure to activate known tyrosine kinases. Consistent with this idea, both angiotensin II and arginine vasopressin have been shown to enhance the mitogenic response of Swiss 3T3 cells and renal proximal tubule cells to epidermal growth factor, 12 -14 which stimulates tyrosine kinase activity but does not induce a calcium transient. 35 Rozengurt et al 12 reported that arginine vasopressin enhanced the mitogenic response of Swiss 3T3 cells to epidermal growth factor plus insulin to levels comparable with that of 10% FBS. Thus, both arginine vasopressin and angiotensin II can enhance the proliferative response of a tyrosine kinase activating growth factor. It is thus interesting to speculate that angiotensin II and arginine vasopressin may function as weak mitogens for vascular smooth muscle cells, stimulating only the increase in protein content associated with cell cycle progression but not cell division. Alternatively, angiotensin II and arginine vasopressin-induced smooth muscle cell hypertrophy may occur by mechanisms distinct from normal cell cycle progression and may represent an adaptive growth response to match tissue mass and function. Which of these mechanisms is operative remains to be determined.
Campbell-Boswell and Robertson
16 have previously reported that arginine vasopressin inhibited proliferation of human aortic smooth muscle cells grown in media containing either 5% or 10% FBS, but had no significant effect at lower serum concentrations. In contrast, in the present studies arginine vasopressin had no effect on cell number in media containing either 10% or 0.4% FBS. CampbellBoswell and Robertson also observed that cells maintained in 5% human platelet-poor plasma responded to 1 fiM arginine vasopressin with a 15% increase in cell number over 7 days. However, they did not address whether this reflected stimulation of cellular proliferation or an increase in cell viability in arginine vasopressin-treated samples. Consistent with our observation of an arginine vasopressininduced increase in protein content, CampbellBoswell and Robertson did note an increase in cell size but did not characterize or directly measure cell mass or protein content. 16 The different results obtained by Campbell-Boswell and Robertson and ourselves with respect to mitogenic activity of arginine vasopressin may reflect differences in species, serum components, or state of differentiation of the cells. Their human smooth muscle cells were obtained with an explant procedure and presumably express few, if any, smooth muscle specific contractile proteins, 36 whereas our cells, which were obtained with an enzyme dispersal protocol, have been shown to express high levels of a number of smooth musclespecific contractile proteins, including smooth muscle a-actin, 18 smooth muscle myosin heavy chains, 37 smooth muscle light chains, 38 and tropomyosin (G. Owens, unpublished observations).
Arginine vasopressin was very potent in inducing smooth muscle cell hypertrophy. The potency of the response and the fact that arginine vasopressininduced increases in [ 35 S]methionine incorporation can be blocked by the specific V\ receptor antagonist, [l-)3-mercapto-)3,/3-cyclopentamethylene propionic acid),2-(O-methyl)tyrosine]arginine vasopressin provide strong evidence that the response is receptor mediated. Although the increases in protein content observed in these studies were small compared with the changes observed in conjunction with cellular proliferation, they are similar in magnitude to that observed in diploid smooth muscle cells in vivo in the spontaneously hypertensive rat. Furthermore, a 35% increase in total cellular protein content in the absence of cell division represents a substantial change in cell mass.
It is of interest to note that arginine vasopressininduced increases in [ 35 S]methionine incorporation occurred more rapidly than that observed previously for angiotensin II (less than 6 hours for arginine vasopressin vs. 6-9 hours for angiotensin II) and that the treatment time required to induce this increase was also significantly shorter (5 minutes for arginine vasopressin vs. 2-3 hours for angiotensin II). Thus, even though both angiotensin II and arginine vasopressin (V,) receptors are thought to be G-protein dependent and have many of the same intracellular signaling events and cellular responses, the mechanisms whereby they induce cultured smooth muscle cell hypertrophy may differ. Observations that cotreatment of quiescent smooth muscle cells with arginine vasopressin and angiotensin II induced further increases in both protein content and [ 35 S]methionine incorporation than that with either agonist alone support this idea. However, the effects of these agonists were not additive ( Figure 7) . Thus, the possibility that neither agonist alone was sufficient to maximally activate the same signaling pathways, possibly due to limits in receptor number, receptor coupling mechanisms, or tachyphylaxis must be considered.
An obvious question is whether contractile agonists are important growth mediators for smooth muscle cells in vivo. Although the cultured smooth muscle cells used in these studies continue to express smooth muscle specific characteristics, these cells are obviously not identical to those found in vivo. Furthermore, we have studied a simplified system, and the influences of factors such as extracellular matrix as well as cell-cell interaction in the response have not yet been explored. Nevertheless, there is suggestive evidence that contractile agonists may have growth modulatory properties in vivo, 8 -11 and it is hoped that studies of simplified models may help to identify important regulators of hypertrophy in vivo.
In summary, the results of this study support the hypothesis that vasoconstrictors are hypertrophic agents for quiescent cultured rat aortic smooth muscle cells. Further studies are required to determine whether the increase in protein content is due to a generalized increase in all proteins or a specific subset of proteins and to identify which intracellular signaling mechanisms are important for the hypertrophic response.
